{
  "updated": "2026-05-20",
  "disclosure": "Peptide Checker regulatory pages summarize public sources for buyer verification. They are not legal or medical advice.",
  "pages": [
    {
      "title": "TGA Peptide Watchlist Australia",
      "slug": "tga-peptide-watchlist",
      "url": "https://peptidecheck.com.au/regulatory/tga-peptide-watchlist/",
      "summary": "On 13 April 2026, the TGA published a safety advisory on unapproved peptide products. It names BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 as examples and warns that unclear labels, code-only products, research-use disclaimers, and public advertising can still create regulatory and public-health risk.",
      "points": [
        "The TGA says peptide products are regulated as therapeutic goods in Australia.",
        "The advisory names BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 as examples of unapproved peptide products.",
        "The TGA warns that unapproved products have not been assessed for safety, quality, or effectiveness.",
        "Products identified only by codes or unclear labels may not be assessed for release under the Personal Importation Scheme.",
        "A research-use-only disclaimer does not by itself change regulatory status, permit importation, or remove advertising and supply obligations."
      ],
      "scheduleRows": [],
      "trackerRows": [],
      "sourceLinks": [
        [
          "TGA unapproved peptide products safety advisory",
          "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products"
        ]
      ]
    },
    {
      "title": "GLP-1 Compounding Ban Australia 2024",
      "slug": "glp1-compounding-ban-2024-au",
      "url": "https://peptidecheck.com.au/regulatory/glp1-compounding-ban-2024-au/",
      "summary": "The TGA says amendments to the Therapeutic Goods Regulations 1990 mean compounded GLP-1 RA products are no longer able to be compounded by pharmacists and supplied to patients. The change applies to GLP-1 RA analogues compounded on or after 1 October 2024.",
      "points": [
        "The TGA announced the change on 18 June 2024.",
        "The amendments apply to all medicines containing GLP-1 RA analogues, regardless of dosage form, compounded on or after 1 October 2024.",
        "Your Solution Compounding Pharmacy later gave a court-enforceable undertaking about advertising prescription-only compounded weight-loss medicines.",
        "Peptide Checker treats GLP-1 clinic pages as a separate lane from grey-market research peptide stores.",
        "A clinic-model score needs prescription path, clinician path, pharmacy path, advertising compliance, and current supply evidence."
      ],
      "scheduleRows": [],
      "trackerRows": [],
      "sourceLinks": [
        [
          "TGA GLP-1 RA pharmacy compounding changes",
          "https://www.tga.gov.au/news/media-releases/update-glucagon-peptide-1-receptor-agonists-glp-1-ras-pharmacy-compounding-changes"
        ],
        [
          "TGA Your Solution Compounding Pharmacy undertaking",
          "https://www.tga.gov.au/news/media-releases/your-solution-compounding-pharmacy-undertakes-comply-advertising-rules-weight-loss-medicines"
        ]
      ]
    },
    {
      "title": "Peptide Customs Seizure Australia",
      "slug": "customs-seizure-explained",
      "url": "https://peptidecheck.com.au/regulatory/customs-seizure-explained/",
      "summary": "The TGA warns that unapproved peptide products with unclear labelling, code-only identification, omitted ingredients, obscured information, or unlabelled vials may not be considered for release under the Personal Importation Scheme. A joint ABF/TGA release in April 2026 also reported seizures of PIEDs, steroids, and peptide products in an alleged importation syndicate investigation.",
      "points": [
        "Ask where the first tracking scan begins, not just where the website says it ships.",
        "Treat code-only labels as a serious verification problem.",
        "Save the product page, invoice, tracking, and support replies before payment if the dispatch route is unclear.",
        "Do not treat research-use language as an import shield.",
        "The safer pre-payment question is: can this vendor explain the import, prescription, research, or pharmacy pathway with sources?"
      ],
      "scheduleRows": [],
      "trackerRows": [],
      "sourceLinks": [
        [
          "TGA unapproved peptide products safety advisory",
          "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products"
        ],
        [
          "TGA and ABF seizure release",
          "https://www.tga.gov.au/news/media-releases/three-victorians-arrested-following-seizure-over-2-million-worth-steroids-and-peptides-abf-and-tga"
        ]
      ]
    },
    {
      "title": "TGA Peptide and Compounding Enforcement Actions",
      "slug": "tga-enforcement-actions-2026",
      "url": "https://peptidecheck.com.au/regulatory/tga-enforcement-actions-2026/",
      "summary": "Peptide Checker does not apply an enforcement penalty to a vendor unless the public source is attached to that vendor profile. This index records market-relevant TGA actions and explains how each case should and should not be used.",
      "points": [
        "Switch Nutrition: the TGA says it issued 4 infringement notices totalling $79,200 for alleged unlawful advertising involving therapeutic goods.",
        "Victorian peptide import case: the TGA says it issued one $3,756 infringement notice for alleged unlawful importation of a peptide in 2024.",
        "Victorian unapproved medicines case: the TGA says it issued 3 notices totalling $11,268 in 2025 for unapproved prescription-only medicines; the imported products named there were modafinil and armodafinil, not peptides.",
        "Your Solution Compounding Pharmacy: the TGA accepted a court-enforceable undertaking about advertising prescription-only compounded medicines for weight loss.",
        "ABF/TGA seizure: the joint release reported more than $2 million worth of PIEDs, illicit steroids, and peptide products seized in an alleged syndicate investigation."
      ],
      "scheduleRows": [],
      "trackerRows": [],
      "sourceLinks": [
        [
          "TGA Switch Nutrition infringement notices",
          "https://www.tga.gov.au/news/media-releases/tga-issues-infringement-notices-alleged-unlawful-advertising-therapeutic-goods-involving-prohibited-representations"
        ],
        [
          "TGA Victorian fined for allegedly importing unapproved peptide",
          "https://www.tga.gov.au/news/media-releases/victorian-fined-allegedly-importing-unapproved-peptide"
        ],
        [
          "TGA Victorian further infringement notices",
          "https://www.tga.gov.au/news/media-releases/victorian-issued-further-infringement-notices-allegedly-importing-unapproved-therapeutic-goods"
        ],
        [
          "TGA Your Solution Compounding Pharmacy undertaking",
          "https://www.tga.gov.au/news/media-releases/your-solution-compounding-pharmacy-undertakes-comply-advertising-rules-weight-loss-medicines"
        ],
        [
          "TGA and ABF seizure release",
          "https://www.tga.gov.au/news/media-releases/three-victorians-arrested-following-seizure-over-2-million-worth-steroids-and-peptides-abf-and-tga"
        ]
      ]
    },
    {
      "title": "Personal Importation Scheme Peptides Australia 2026",
      "slug": "personal-importation-scheme-2026",
      "url": "https://peptidecheck.com.au/regulatory/personal-importation-scheme-2026/",
      "summary": "The TGA says the Personal Importation Scheme can allow individuals to import therapeutic goods not entered in the ARTG only if all conditions are met. Those conditions include personal or immediate-family use, no supply to anyone else, a valid Australian prescription or written authority for prescription-only medicines, no more than a 3-month supply in a single order, no more than a 15-month supply in 12 months, no controlled substances, and clear labels. Counterfeit products are prohibited under any circumstances.",
      "points": [
        "Do not treat the phrase personal importation as legal advice from a seller.",
        "If the medicine is prescription-only in Australia, the TGA says the importer must hold a valid Australian prescription or written authority at the time of importation.",
        "The TGA says one import cannot exceed a 3-month supply at the maximum prescribed dose for prescription-only medicines or manufacturer-recommended dose for non-prescription goods.",
        "The TGA says total quantity imported within any 12-month period must not exceed a 15-month supply.",
        "The TGA says products must be for the individual or immediate family member only and cannot be sold, supplied, or given away.",
        "The TGA warns counterfeit products are prohibited from importation even if the buyer has a prescription.",
        "The TGA says unclear, mismatched, or missing labels can stop products being released because identity cannot be confirmed.",
        "Peptide Checker did not find a primary TGA source for the claimed February 2026 formal-declaration rule in this pass, so that claim is not published as fact."
      ],
      "scheduleRows": [],
      "trackerRows": [],
      "sourceLinks": [
        [
          "TGA Personal Importation Scheme",
          "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme"
        ],
        [
          "TGA unapproved peptide products safety advisory",
          "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products"
        ],
        [
          "TGA importing medicine or medical device",
          "https://www.tga.gov.au/products/importing-medicine-or-medical-device"
        ]
      ]
    },
    {
      "title": "Australian Peptide Scheduling Map",
      "slug": "peptide-scheduling-map",
      "url": "https://peptidecheck.com.au/regulatory/peptide-scheduling-map/",
      "summary": "The TGA says the Poisons Standard classifies medicines and poisons into schedules reflecting risk and recommended controls. Peptide Checker only marks a compound as scheduled where a primary TGA or government source is attached. Where the public record is a warning, advisory, or adjacent source rather than a schedule entry, the page says that plainly.",
      "points": [
        "Schedule 4 means prescription-only medicine or prescription animal remedy; it is not a retail permission slip.",
        "BPC-157 has a source-backed Schedule 4 decision in TGA scheduling material.",
        "TGA scheduling material lists CJC-1295, pralmorelin/GHRP-2, GHRP-6, GHRHs, GHRPs, GHSs, hexarelin, ipamorelin, thymosin beta 4, TB-500, and fibroblast growth factors as Schedule 4 and Appendix D Part 5 substances.",
        "The TGA's 2026 peptide advisory names BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 as examples of unapproved peptide products, but that advisory is not the same thing as a schedule entry for every named compound.",
        "Sport Integrity Australia says somatropin, human growth hormone, is approved by the TGA for prescription medicines. Peptide Checker does not repeat the claim that HGH is Schedule 8 because the source-backed Australian signal found in this pass points to Schedule 4 prescribing control.",
        "If a vendor says research use only, that does not remove prescription, advertising, import, or supply questions where the product is a therapeutic good."
      ],
      "scheduleRows": [
        {
          "compound": "BPC-157",
          "status": "Schedule 4 source found",
          "buyerUse": "Treat BPC-157 legality claims as prescription-control and unapproved-product questions, not as ordinary supplement language.",
          "source": [
            "TGA BPC-157 final scheduling decision",
            "https://www.tga.gov.au/sites/default/files/2024-05/notice-final-decisions-amend-not-amend-current-poisons-standard-november-2023.pdf"
          ]
        },
        {
          "compound": "TB-500 and thymosin beta 4",
          "status": "Schedule 4 and Appendix D source found",
          "buyerUse": "A seller offering TB-500 should be checked against prescription-only advertising, supply, import, and proof standards.",
          "source": [
            "TGA PIED scheduling material",
            "https://www.tga.gov.au/sites/default/files/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-nov-2017.pdf"
          ]
        },
        {
          "compound": "CJC-1295, Ipamorelin, Hexarelin, GHRP-2, GHRP-6, GHRHs, GHRPs, and GHSs",
          "status": "Schedule 4 and Appendix D source found",
          "buyerUse": "Growth-hormone pathway peptide claims need prescription and advertising scrutiny before any retail trust is earned.",
          "source": [
            "TGA PIED scheduling material",
            "https://www.tga.gov.au/sites/default/files/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-nov-2017.pdf"
          ]
        },
        {
          "compound": "GHK-Cu",
          "status": "Named in TGA unapproved-peptide advisory",
          "buyerUse": "Peptide Checker tracks it as a TGA-named unapproved peptide example; a separate schedule-entry source still needs to be attached before schedule language is used.",
          "source": [
            "TGA unapproved peptide products safety advisory",
            "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products"
          ]
        },
        {
          "compound": "Retatrutide",
          "status": "Named in TGA unapproved-peptide advisory",
          "buyerUse": "Retatrutide pages should be read through GLP-1, counterfeit, unapproved-product, and import-risk evidence, not seller purity slogans.",
          "source": [
            "TGA unapproved peptide products safety advisory",
            "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products"
          ]
        },
        {
          "compound": "Melanotan II",
          "status": "Schedule 4 source found in TGA enforcement undertaking",
          "buyerUse": "Melanotan II appears in TGA enforcement material as a Schedule 4 prescription-only substance, so public advertising and retail claims deserve extra scrutiny.",
          "source": [
            "TGA Net Pharmacy enforceable undertaking",
            "https://www.tga.gov.au/news/compliance-undertakings/enforceable-undertaking-net-pharmacy-pty-ltd"
          ]
        },
        {
          "compound": "Human growth hormone / somatropin",
          "status": "Prescription medicine source found; Schedule 8 claim not used",
          "buyerUse": "Peptide Checker should not call HGH Schedule 8 without a primary schedule source. The source-backed signal in this pass is prescription-medicine control.",
          "source": [
            "Sport Integrity Australia HGH information",
            "https://www.sportintegrity.gov.au/substances/growth-hormone"
          ]
        },
        {
          "compound": "MOTS-C, Tesamorelin, IGF-1 LR3, PT-141, DSIP, Epitalon",
          "status": "Evidence pending in this map",
          "buyerUse": "These belong in the buyer search map, but schedule status should stay pending until a primary Australian source is attached.",
          "source": [
            "TGA Poisons Standard overview",
            "https://www.tga.gov.au/resources/legislation/poisons-standard"
          ]
        }
      ],
      "trackerRows": [],
      "sourceLinks": [
        [
          "TGA Poisons Standard overview",
          "https://www.tga.gov.au/resources/legislation/poisons-standard"
        ],
        [
          "TGA BPC-157 final scheduling decision",
          "https://www.tga.gov.au/sites/default/files/2024-05/notice-final-decisions-amend-not-amend-current-poisons-standard-november-2023.pdf"
        ],
        [
          "TGA PIED scheduling material",
          "https://www.tga.gov.au/sites/default/files/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-nov-2017.pdf"
        ],
        [
          "TGA unapproved peptide products safety advisory",
          "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products"
        ],
        [
          "TGA Net Pharmacy enforceable undertaking",
          "https://www.tga.gov.au/news/compliance-undertakings/enforceable-undertaking-net-pharmacy-pty-ltd"
        ],
        [
          "Sport Integrity Australia HGH information",
          "https://www.sportintegrity.gov.au/substances/growth-hormone"
        ]
      ]
    },
    {
      "title": "TGA Peptide Enforcement Tracker",
      "slug": "tga-enforcement-tracker",
      "url": "https://peptidecheck.com.au/regulatory/tga-enforcement-tracker/",
      "summary": "The current tracker records 9 public TGA actions relevant to the peptide and adjacent clinic-market trust problem. Monetary penalties and infringement notices visible in the tracker total at least $10,242,748, excluding the Your Solution Compounding Pharmacy undertaking because no penalty amount is attached to that public record.",
      "points": [
        "Peptide Clinics Pty Ltd remains the benchmark Australian peptide-advertising case because the Federal Court ordered a $10 million civil penalty.",
        "Your Solution Compounding Pharmacy is included as an adjacent GLP-1 and compounded-weight-loss advertising undertaking, not a peptide-vendor fine.",
        "The April 2024 Victorian case is the peptide-specific import infringement in this tracker.",
        "The September 2025 Victorian case involved modafinil and armodafinil, not peptides, and is included as repeat personal-import enforcement context.",
        "The December 2025 NSW case and January 2026 6-individual case are cosmetic-injectable and unapproved-therapeutic-goods enforcement context.",
        "Switch Nutrition is included as therapeutic-goods advertising enforcement involving prohibited representations, not as a peptide vendor page.",
        "The 2022 NSW medical-practitioner import case is included as a personal-import and prescription-only import warning, not a peptide-specific case.",
        "Caruso's Natural Health is included because it shows mainstream listed-medicine sponsors can be penalised when evidence behind therapeutic uses is not held.",
        "No vendor-specific TGA penalty is applied unless the vendor page links the public source directly."
      ],
      "scheduleRows": [],
      "trackerRows": [
        {
          "date": "23 July 2019",
          "caseName": "Peptide Clinics Pty Ltd",
          "category": "Peptide advertising and prescription-only medicines",
          "penalty": "$10,000,000 Federal Court civil penalty",
          "buyerUse": "Benchmark case for clinic-model peptide advertising and implied medical oversight.",
          "source": [
            "TGA $10 million Peptide Clinics penalty",
            "https://www.tga.gov.au/news/media-releases/10-million-penalty-ordered-against-peptide-clinics-pty-ltd-advertising-breaches"
          ]
        },
        {
          "date": "2024 advertising period, undertaking published later",
          "caseName": "Your Solution Compounding Pharmacy",
          "category": "Compounded weight-loss medicine advertising",
          "penalty": "Court-enforceable undertaking - no monetary penalty in source",
          "buyerUse": "Clinic-model and GLP-1 advertising compliance context.",
          "source": [
            "TGA Your Solution Compounding Pharmacy undertaking",
            "https://www.tga.gov.au/news/media-releases/your-solution-compounding-pharmacy-undertakes-comply-advertising-rules-weight-loss-medicines"
          ]
        },
        {
          "date": "29 April 2024",
          "caseName": "Victorian individual",
          "category": "Peptide import infringement",
          "penalty": "$3,756 infringement notice",
          "buyerUse": "Peptide-specific personal-import enforcement context.",
          "source": [
            "TGA Victorian peptide import notice",
            "https://www.tga.gov.au/news/media-releases/victorian-fined-allegedly-importing-unapproved-peptide"
          ]
        },
        {
          "date": "25 September 2025",
          "caseName": "Victorian individual, further notices",
          "category": "Prescription-only medicine import infringement",
          "penalty": "$11,268 across 3 infringement notices",
          "buyerUse": "Repeat personal-import enforcement context; TGA names modafinil and armodafinil, not peptides.",
          "source": [
            "TGA Victorian further notices",
            "https://www.tga.gov.au/news/media-releases/victorian-issued-further-infringement-notices-allegedly-importing-unapproved-therapeutic-goods"
          ]
        },
        {
          "date": "18 December 2025",
          "caseName": "NSW-based individual",
          "category": "Cosmetic-injectable and prescription-only medicine import infringement",
          "penalty": "$19,800 across 5 infringement notices",
          "buyerUse": "Adjacent import-risk context for injectables and unapproved prescription-only medicines.",
          "source": [
            "TGA NSW cosmetic injectables import notice",
            "https://www.tga.gov.au/news/media-releases/nsw-based-individual-issued-infringement-notices-allegedly-importing-cosmetic-injectables"
          ]
        },
        {
          "date": "29 January 2026",
          "caseName": "6 individuals",
          "category": "Unapproved therapeutic-goods import and advertising infringement",
          "penalty": "$43,560 across 11 infringement notices",
          "buyerUse": "Broader import, counterfeit, and unlawful advertising context for therapeutic goods.",
          "source": [
            "TGA 6 individuals infringement notices",
            "https://www.tga.gov.au/news/media-releases/tga-issues-infringement-notices-6-individuals-alleged-importation-and-unlawful-advertising-therapeutic-goods"
          ]
        },
        {
          "date": "28 April 2026",
          "caseName": "Switch Nutrition Pty Ltd",
          "category": "Therapeutic-goods advertising infringement",
          "penalty": "$79,200 across 4 infringement notices",
          "buyerUse": "Advertising and prohibited-representation context for wellness and supplement-style claims.",
          "source": [
            "TGA Switch Nutrition infringement notices",
            "https://www.tga.gov.au/news/media-releases/tga-issues-infringement-notices-alleged-unlawful-advertising-therapeutic-goods-involving-prohibited-representations"
          ]
        },
        {
          "date": "18 October 2022",
          "caseName": "NSW-based medical practitioner",
          "category": "Prescription-only medicine import infringement",
          "penalty": "$2,664 infringement notice",
          "buyerUse": "Personal-import and prescription-only medicine import context; not a peptide-specific case.",
          "source": [
            "TGA NSW $2,664 import infringement",
            "https://www.tga.gov.au/news/media-releases/nsw-person-fined-2664-alleged-unlawful-import-prescription-medicines"
          ]
        },
        {
          "date": "13 March 2024",
          "caseName": "Caruso's Natural Health Pty Ltd",
          "category": "Listed-medicine evidence requirements",
          "penalty": "$82,500 across 5 infringement notices",
          "buyerUse": "Mainstream sponsor evidence-context: even listed-medicine therapeutic-use claims need supporting evidence.",
          "source": [
            "TGA Caruso's Natural Health infringement notices",
            "https://www.tga.gov.au/news/media-releases/carusos-natural-health-pty-ltd-fined-alleged-offences-relating-regulatory-requirements"
          ]
        }
      ],
      "sourceLinks": [
        [
          "TGA $10 million Peptide Clinics penalty",
          "https://www.tga.gov.au/news/media-releases/10-million-penalty-ordered-against-peptide-clinics-pty-ltd-advertising-breaches"
        ],
        [
          "TGA Your Solution Compounding Pharmacy undertaking",
          "https://www.tga.gov.au/news/media-releases/your-solution-compounding-pharmacy-undertakes-comply-advertising-rules-weight-loss-medicines"
        ],
        [
          "TGA Victorian peptide import notice",
          "https://www.tga.gov.au/news/media-releases/victorian-fined-allegedly-importing-unapproved-peptide"
        ],
        [
          "TGA Victorian further notices",
          "https://www.tga.gov.au/news/media-releases/victorian-issued-further-infringement-notices-allegedly-importing-unapproved-therapeutic-goods"
        ],
        [
          "TGA NSW cosmetic injectables import notice",
          "https://www.tga.gov.au/news/media-releases/nsw-based-individual-issued-infringement-notices-allegedly-importing-cosmetic-injectables"
        ],
        [
          "TGA 6 individuals infringement notices",
          "https://www.tga.gov.au/news/media-releases/tga-issues-infringement-notices-6-individuals-alleged-importation-and-unlawful-advertising-therapeutic-goods"
        ],
        [
          "TGA Switch Nutrition infringement notices",
          "https://www.tga.gov.au/news/media-releases/tga-issues-infringement-notices-alleged-unlawful-advertising-therapeutic-goods-involving-prohibited-representations"
        ],
        [
          "TGA NSW $2,664 import infringement",
          "https://www.tga.gov.au/news/media-releases/nsw-person-fined-2664-alleged-unlawful-import-prescription-medicines"
        ],
        [
          "TGA Caruso's Natural Health infringement notices",
          "https://www.tga.gov.au/news/media-releases/carusos-natural-health-pty-ltd-fined-alleged-offences-relating-regulatory-requirements"
        ]
      ]
    },
    {
      "title": "Peptide Adverse Event Reporting Australia",
      "slug": "adverse-event-reporting-peptides-australia",
      "url": "https://peptidecheck.com.au/regulatory/adverse-event-reporting-peptides-australia/",
      "summary": "The TGA's Database of Adverse Event Notifications, DAEN, is a public database of adverse event reports for medicines and vaccines. A report in DAEN does not prove that a medicine caused the event, but it can show safety signals that deserve careful review. Peptide Checker uses this page to explain what evidence buyers should preserve if they suspect harm from a peptide product.",
      "points": [
        "Do not use DAEN as a simple guilt database. A report is a signal, not proof of causation.",
        "Preserve the vial, box, batch number, COA, invoice, product page, tracking, payment record, and support messages.",
        "Write a timeline before memory drifts: when the product arrived, storage conditions, when it was used, what happened, and when care was sought.",
        "Keep clinician notes, pathology results, hospital paperwork, and photos where relevant.",
        "Report suspected adverse events through the TGA pathway and speak to a qualified health professional where health is involved.",
        "If the supplier cannot connect the product to a batch-matched COA after a suspected event, that missing record becomes part of the trust problem."
      ],
      "scheduleRows": [],
      "trackerRows": [],
      "sourceLinks": [
        [
          "TGA Database of Adverse Event Notifications",
          "https://www.tga.gov.au/database-adverse-event-notifications-daen"
        ],
        [
          "TGA how to search the DAEN medicines",
          "https://www.tga.gov.au/safety/database-adverse-event-notifications-daen/tips-searching-database-adverse-event-notifications-daen"
        ],
        [
          "DAEN medicines search",
          "https://aems.tga.gov.au/daen-medicines-search/"
        ]
      ]
    },
    {
      "title": "ARTG Approved Peptide Medicines Australia",
      "slug": "artg-approved-peptide-medicines",
      "url": "https://peptidecheck.com.au/regulatory/artg-approved-peptide-medicines/",
      "summary": "The Australian Register of Therapeutic Goods, ARTG, is the public register for therapeutic goods that can be supplied in Australia. Buyers should use it to check product name, sponsor, active ingredients, dosage form, warnings, start date, and whether the product is listed, registered, included, or export-only. A research peptide storefront should not be treated as approved unless the exact product record supports that claim.",
      "points": [
        "Ask for the AUST R, AUST L, or ARTG identifier when a seller uses approved, registered, listed, or TGA language.",
        "Search the exact product name, sponsor, and active ingredient in the ARTG, not just the vendor's brand name.",
        "Check whether the dosage form and active ingredient match the vial, capsule, nasal spray, or compounded product being sold.",
        "Do not treat an approved ingredient, overseas approval, or a lab COA as Australian product approval.",
        "If a clinic or supplier uses pharmacy or compounding language, check the prescribing, dispensing, compounding, and advertising path separately.",
        "If the seller cannot provide an ARTG pathway, the page should say evidence pending rather than turning approval language into proof."
      ],
      "scheduleRows": [],
      "trackerRows": [],
      "sourceLinks": [
        [
          "TGA searching the ARTG",
          "https://www.tga.gov.au/searching-australian-register-therapeutic-goods-artg"
        ],
        [
          "TGA ARTG search",
          "https://www.tga.gov.au/resources/artg"
        ],
        [
          "TGA unapproved peptide products safety advisory",
          "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products"
        ]
      ]
    },
    {
      "title": "Peptide Advertising Claims Australia",
      "slug": "peptide-advertising-claims-australia",
      "url": "https://peptidecheck.com.au/regulatory/peptide-advertising-claims-australia/",
      "summary": "The TGA regulates advertising of therapeutic goods in Australia and explains that some goods, including prescription medicines and other restricted goods, cannot be advertised to the public. For peptide buyers, the practical check is whether a page turns research, wellness, recovery, fat-loss, injury, hormone, or anti-ageing language into a therapeutic outcome claim before the evidence and lawful pathway are visible.",
      "points": [
        "Do not treat research-use-only wording as a free pass if the same page makes treatment, healing, weight-loss, hormone, anti-ageing, or injury-recovery claims.",
        "Check whether testimonials, before-after content, and influencer codes are being used to imply outcomes that the seller cannot advertise directly.",
        "If a product is prescription-only or otherwise restricted, public advertising can be a compliance problem even when checkout still works.",
        "Advertising-risk findings should be tied to the exact page, screenshot date, claim language, and source URL.",
        "Peptide Checker should not say a vendor breached the law without a regulator or court source. It can still say the claim needs advertising-risk review.",
        "Every vendor page should separate product proof, legal pathway proof, and advertising-risk proof instead of collapsing them into one trust score."
      ],
      "scheduleRows": [],
      "trackerRows": [],
      "sourceLinks": [
        [
          "TGA advertising basics for therapeutic goods",
          "https://www.tga.gov.au/products/regulations-all-products/advertising/advertising-basics"
        ],
        [
          "TGA what can and cannot be advertised",
          "https://www.tga.gov.au/products/regulations-all-products/advertising/advertising-basics/what-can-and-cannot-be-advertised-general-public"
        ],
        [
          "TGA unapproved peptide products safety advisory",
          "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products"
        ]
      ]
    },
    {
      "title": "Peptide Sciences Shutdown Australia Search Guide",
      "slug": "peptide-sciences-shutdown-australia",
      "url": "https://peptidecheck.com.au/regulatory/peptide-sciences-shutdown-australia/",
      "summary": "Peptide Dossier reports Peptide Sciences shut down on 6 March 2026, gave no guidance for pending orders, had operated for more than a decade, and generated an estimated US$7.4M in monthly online sales as of December 2025 according to Grips Intelligence. Peptide Checker tracks it as a closed-vendor incident page, not as an active AU supplier.",
      "points": [
        "Preserve order confirmation, payment receipt, tracking, emails, and screenshots before starting any dispute.",
        "Do not assume an alternative vendor is safer because it appears in a shutdown article.",
        "Check the replacement vendor's batch records, COAs, ownership, payment recourse, and right-of-reply status.",
        "Use the Peptide Sciences page to understand the incident, then use the vendor pages to verify current suppliers.",
        "Peptide Checker phrases Peptide Sciences shutdown claims as secondary-source reports unless original company or regulator sources are attached."
      ],
      "scheduleRows": [],
      "trackerRows": [],
      "sourceLinks": [
        [
          "Peptide Dossier Peptide Sciences shutdown analysis",
          "https://peptidedossier.com/guides/peptide-sciences-shutdown/"
        ],
        [
          "Peptide Checker Peptide Sciences incident page",
          "https://peptidecheck.com.au/vendors/peptide-sciences/"
        ]
      ]
    }
  ]
}